Editor's Note: In the video below, Olysio's sales for the quarter are identified as $365 million. Olysio's actual sales were $354 million. The Fool regrets the error.
Johnson and Johnson (NYSE: JNJ ) reported quarterly earnings on Tuesday, and one division stood out as the clear growth driver: pharma. With 11% growth reported, it easily outpaced revenue growth the other two main components of JNJ's business -- consumer goods, which declined over 3%, and medical devices and diagnostics, which was basically flat.
A number of drugs contributed to this impressive growth, with revenue from Stelara for plaque psoriasis and psoriatic arthritis up 32% year-over-year to $456 million and Zytiga for metastatic castration-resistant prostate cancer up 49% to $512 million. Remicade continued its solid performance, up slightly to $1.6 billion in sales for the quarter.
In this video, taken from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass dig into the pharma segment and discuss the one drug which surprised investors with its strong performance last quarter -- could it become a blockbuster?
Is Johnson and Johnson a top dividend stock for the next decade?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.